Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 233FT | — |
adult patient received a pediatric dose of Engerix B; adult patient received a pediatric dose of Engerix B; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 47-year-old female patient who received HBV (Engerix B pediatric) (batch number 233FT, expiry date 12-DEC-2025) for prophylaxis. On 14-MAR-2025, the patient received Engerix B pediatric. On 14-MAR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: adult patient received a pediatric dose of Engerix B) and underdose (Verbatim: adult patient received a pediatric dose of Engerix B). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-MAR-2025 The nurse called to inform that on 14th March 2025 an adult patient received a pediatric dose of Engerix B which led to adult use of a child product and underdose. Should administer another pediatric dose? The vaccine administration facility is the same as primary reporter.